Bank of New York Mellon’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.28M | Buy |
305,258
+5,227
| +2% | +$73.3K | ﹤0.01% | 2358 |
|
|
2025
Q1 | $4.69M | Sell |
300,031
-4,976
| -2% | -$77.8K | ﹤0.01% | 2249 |
|
|
2024
Q4 | $4.25M | Sell |
305,007
-6,052
| -2% | -$84.3K | ﹤0.01% | 2368 |
|
|
2024
Q3 | $2.89M | Sell |
311,059
-79,143
| -20% | -$736K | ﹤0.01% | 2569 |
|
|
2024
Q2 | $3.63M | Buy |
390,202
+80,078
| +26% | +$745K | ﹤0.01% | 2487 |
|
|
2024
Q1 | $3.07M | Sell |
310,124
-7,803
| -2% | -$77.3K | ﹤0.01% | 2544 |
|
|
2023
Q4 | $1.03M | Buy |
317,927
+80,148
| +34% | +$259K | ﹤0.01% | 3171 |
|
|
2023
Q3 | $1.26M | Buy |
237,779
+27,170
| +13% | +$144K | ﹤0.01% | 3034 |
|
|
2023
Q2 | $2.01M | Buy |
210,609
+74,454
| +55% | +$710K | ﹤0.01% | 2827 |
|
|
2023
Q1 | $1.5M | Buy |
136,155
+4,782
| +4% | +$52.6K | ﹤0.01% | 2948 |
|
|
2022
Q4 | $1.94M | Buy |
131,373
+6,764
| +5% | +$100K | ﹤0.01% | 2864 |
|
|
2022
Q3 | $2.38M | Buy |
124,609
+29,182
| +31% | +$558K | ﹤0.01% | 2738 |
|
|
2022
Q2 | $2.03M | Sell |
95,427
-919
| -1% | -$19.6K | ﹤0.01% | 2823 |
|
|
2022
Q1 | $1.86M | Sell |
96,346
-1,177
| -1% | -$22.7K | ﹤0.01% | 2974 |
|
|
2021
Q4 | $2.02M | Buy |
97,523
+2,459
| +3% | +$51K | ﹤0.01% | 2989 |
|
|
2021
Q3 | $2.27M | Buy |
95,064
+7,985
| +9% | +$191K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $2.38M | Buy |
87,079
+178
| +0.2% | +$4.86K | ﹤0.01% | 2878 |
|
|
2021
Q1 | $2.51M | Buy |
86,901
+20,374
| +31% | +$589K | ﹤0.01% | 2791 |
|
|
2020
Q4 | $1.87M | Buy |
66,527
+9,916
| +18% | +$279K | ﹤0.01% | 2886 |
|
|
2020
Q3 | $1.66M | Buy |
56,611
+21,356
| +61% | +$626K | ﹤0.01% | 2772 |
|
|
2020
Q2 | $1.07M | Buy |
35,255
+11,171
| +46% | +$338K | ﹤0.01% | 3075 |
|
|
2020
Q1 | $718K | Buy |
+24,084
| New | +$718K | ﹤0.01% | 3188 |
|